Arnie Pye
Senior Member (Voting Rights)
A review from a cardiologist of the meta-analysis posted in the original post in this thread :
Fawning Coverage of New Antidepressants Review Masks Key Caveats
Fawning Coverage of New Antidepressants Review Masks Key Caveats
A recent review and meta-analysis of 522 randomised trials, including about 117,000 participants suffering from depression, has concluded that all antidepressants are better than a dummy tablet.
While numerous studies were included, the analysis and review itself seem to be mathematical and unidimensional. The number of patients in these studies is too small and the follow-up too brief to make a convincing argument about effectiveness. It is well known that antidepressant pills take as long as a month to kick in, that dropout rates are high (as much as 400% more than placebo), while their efficacy as compared to placebo is marginal in clinical terms.
As a cardiologist, I am concerned that amitriptyline, a tricyclic antidepressant developed in the 1950s, has emerged as the most effective antidepressant compared to placebo. Amitriptyline is notorious for triggering sustained ventricular tachycardia. This is a potentially lethal rhythm disturbance that can kill if not treated immediately. Almost every heart patient whose heart has been weakened (by a previous heart attack, hypertension, valvular pathology, etc.) is susceptible to it.